Navigation Links
Savient Pharmaceuticals Submits European Marketing Authorization Application for KRYSTEXXA®
Date:5/4/2011

nts, although not all forward-looking statements contain these identifying words. In particular, any statements regarding the pursuit of our MAA filing in the European Union, the success of our marketing efforts, market demand, and reimbursement, for KRYSTEXXA® and our market expansion plans in other geographical areas are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, our ability to commercialize KRYSTEXXA; our ability to retain the personnel whom we have hired and to hire the remaining personnel necessary to complete the build out of our commercial team; our reliance on third parties to manufacture KRYSTEXXA; the risk that the market for KRYSTEXXA is smaller than we have anticipated; competition from existing therapies and therapies that are currently under development, including therapies that are significantly less expensive than KRYSTEXXA; our ability to gain market acceptance for KRYSTEXXA among physicians, patients, health care payors and others in the medical community; whether we are able to obtain financing, if needed; economic, political and other risks associated with foreign operations; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may
'/>"/>
SOURCE Savient Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
2. Savient Pharmaceuticals to Present Multiple Abstracts at The European League Against Rheumatism (EULAR) 2011 Annual Congress
3. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
4. Savient Pharmaceuticals to Hold First Quarter 2011 Financial Results
5. Savient Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
6. Savient Pharmaceuticals to Present at the 31st Annual Cowen & Co. Health Care Conference
7. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
8. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2010 Results Conference Call on Friday, February 25, 2011
9. Savient Closes Sale of $230 Million in Convertible Senior Notes
10. Savient Announces Proposed Offering of $125 Million in Convertible Senior Notes
11. Savient Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Influenza will affect as many as 200,000 people this year ... as high as 49,000 people.  The main way ... to person in respiratory droplets of coughs and sneezes. ... kills much fewer people each year than the Flu. The ... sweat, saliva, blood and other bodily fluids. The Ebola virus ...
(Date:10/22/2014)... -- Sanomedics International Holdings, Inc. (OTCQB: SIMH) – According ... Data Services, demand for thermometers is expected to grow ... demand for more accurate digital thermometers continues.  ... market for thermometers, and one of the companies serving ... Inc. Sanomedics International Holdings designs, develops, markets, ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 Provectus ... dermatology therapies. PV-10, its novel investigational drug for cancer, ... potential for systemic side effects. Its oncology focus is ... Provectus has completed phase 2 trials of PV-10 as ... a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... The Society for Biomolecular Sciences, now officially the ... and Screening (SLAS), invites students, graduate students, post-doctoral associates ... Travel Award to be used for the SBS 17th ... FL, USA. Applicants must be the primary ...
... Nov. 4, 2010 Amylin Pharmaceuticals, Inc. (Nasdaq: ... Conference in Phoenix, Arizona on Thursday, November 11, 2010 at ... M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, ... be webcast live through the "Investors" section of Amylin,s corporate ...
Cached Medicine Technology:Applications Now Being Accepted for SBS 17th Annual Conference & Exhibition Academic Travel Awards 2
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... 22, 2014 Richard Carlson, Managing Partner ... leader with over 25 years experience. Mr. Carlson ... the areas related to EDI, B2B Commerce, RFID and ... Editorial Advisory Board member for Pharmaceutical Commerce Magazine and ... Fin Group is a management and technology consulting firm ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... drinking among young adult men may lead to increased blood ... didn,t cause a similar rise in blood pressure for young ... fact, when young adult women drank lightly or moderately, their ... study found. "This finding parallels studies in older adult ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Women’s health ... in Obstetrics & Gynecology of Columbus, Inc., A Division ... healthcare services to more than 100,000 patients annually. Dr. ... all ages and stages of a women’s life. She ... locations in Westerville and Dublin. , Dr. Murphy ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... , SINGAPORE, June 4 /PRNewswire-Asia/ ... industry will have a unique platform to gain business ... and Congress,2009. According to market analysts, the medical tourism ... market alone will generate revenue,of more than US$4.4 billion ...
... 4 Abbott (NYSE: ABT ) and ... New Drug Application (NDA) to the U.S. Food and ... treatment of mixed dyslipidemia, a combination of two or ... cholesterol), high triglycerides and low HDL-cholesterol (the "good" cholesterol). ...
... Sheets: GOHE) announced today that the company has entered into a ... of a source of high pH water from a premier aquifer. ... annually of this healthy water. , , The water has ... significant natural anti oxidants. , , Charlie Caudle, CEO of ...
... June 4 /PRNewswire/ -- US Oncology, ... aggregate principal amount of senior secured notes to qualified institutional ... of 1933, as amended (the "Securities Act") and outside the ... Act. , , The company plans to use the ...
... 4 Prescribing Reference LLC is pleased to announce that the ... medical professionals as a free download for ... www.empr.com/download ). The MPR Mobile & Desktop Edition ... Microsoft Vista. , , For over 24 years, medical professionals ...
... Advisors, MISSION Skincare(TM) , , NEW YORK, June 4 ... skincare products, is pleased to announce that Brian B. Adams, ... of the world,s most-esteemed athletes as the latest addition to ... of the Board of Advisors, Dr. Adams will play an ...
Cached Medicine News:Health News:Singapore to Host Inaugural Healthcare Travel Exhibition & Congress 2Health News:Singapore to Host Inaugural Healthcare Travel Exhibition & Congress 3Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 2Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 3Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 4Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 5Health News:Go Healthy Enters Letter of Intent to Acquire Premium Water Source 2Health News:US Oncology, Inc. Announces $465 Million Senior Secured Notes Offering 2Health News:MPR Drug Database Available as a Free Download for Mobile Devices, Including BlackBerry and Palm 2Health News:Dr. Brian B. Adams to Join the 'MISSION' 2Health News:Dr. Brian B. Adams to Join the 'MISSION' 3
...
... on decades of experience, the SSD-1000 is ... system. It uses our advanced technologies and ... Using the same technology as our more ... capabilities in a compact and mobile setting., ...
... Harmonic Echo technology constructs images using ... less artifacts and noise than fundamental-frequency ... technology to transmit distortion-free, fundamental-frequency ultrasound ... beam is a pure sinusoidal wave, ...
... Topical Skin Adhesive gives you new options ... intended for topical application only to hold ... from surgical incisions, including punctures from minimally ... lacerations. DERMABOND adhesive may be used in ...
Medicine Products: